Abivax S.A. American Depositary Receipt

Abivax S.A. American Depositary Receipt represents interests in Abivax S.A., a clinical-stage biotechnology company dedicated to developing therapies that harness the body’s natural regulatory mechanisms to treat chronic inflammatory diseases. The company is noted for its innovative approach in modulating immune responses, with its lead product candidate, obefazimod, currently advancing through late-stage clinical trials for ulcerative colitis and in development for Crohn’s disease. Abivax’s focus on microRNA-124 biology underpins its therapeutic pipeline, aiming to offer solutions for conditions characterized by immune dysregulation. The American Depositary Receipt (ADR) facilitates access for international investors by allowing exposure to Abivax’s equity in the form of U.S.-denominated securities, each corresponding to one underlying ordinary share of Abivax S.A. This structure supports broader participation from global markets, emphasizing Abivax’s role in the dynamic biotechnology sector targeting unmet medical needs in immunology and gastroenterology.